Literature DB >> 21689896

Acute administration of vinpocetine, a phosphodiesterase type 1 inhibitor, ameliorates hyperactivity in a mice model of fetal alcohol spectrum disorder.

Fernanda Nunes1, Kélvia Ferreira-Rosa, Maurício Dos S Pereira, Regina C Kubrusly, Alex C Manhães, Yael Abreu-Villaça, Cláudio C Filgueiras.   

Abstract

BACKGROUND: Maternal alcohol use during pregnancy causes a continuum of long-lasting disabilities in the offspring, commonly referred to as fetal alcohol spectrum disorder (FASD). Attention-deficit/hyperactivity disorder (ADHD) is possibly the most common behavioral problem in children with FASD and devising strategies that ameliorate this condition has great clinical relevance. Studies in rodent models of ADHD and FASD suggest that impairments in the cAMP signaling cascade contribute to the hyperactivity phenotype. In this work, we investigated whether the cAMP levels are affected in a long-lasting manner by ethanol exposure during the third trimester equivalent period of human gestation and whether the acute administration of the PDE1 inhibitor vinpocetine ameliorates the ethanol-induced hyperactivity.
METHODS: From postnatal day (P) 2 to P8, Swiss mice either received ethanol (5g/kg i.p.) or saline every other day. At P30, the animals either received vinpocetine (20mg/kg or 10mg/kg i.p.) or vehicle 4h before being tested in the open field. After the test, frontal cerebral cortices and hippocampi were dissected and collected for assessment of cAMP levels.
RESULTS: Early alcohol exposure significantly increased locomotor activity in the open field and reduced cAMP levels in the hippocampus. The acute treatment of ethanol-exposed animals with 20mg/kg of vinpocetine restored both their locomotor activity and cAMP levels to control levels.
CONCLUSIONS: These data lend support to the idea that cAMP signaling system contribute to the hyperactivity induced by developmental alcohol exposure and provide evidence for the potential therapeutic use of vinpocetine in FASD.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21689896     DOI: 10.1016/j.drugalcdep.2011.05.024

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  12 in total

1.  Early alcohol exposure disrupts visual cortex plasticity in mice.

Authors:  Crystal L Lantz; Weili Wang; Alexandre E Medina
Journal:  Int J Dev Neurosci       Date:  2012-05-14       Impact factor: 2.457

Review 2.  Clinical and molecular genetics of the phosphodiesterases (PDEs).

Authors:  Monalisa F Azevedo; Fabio R Faucz; Eirini Bimpaki; Anelia Horvath; Isaac Levy; Rodrigo B de Alexandre; Faiyaz Ahmad; Vincent Manganiello; Constantine A Stratakis
Journal:  Endocr Rev       Date:  2013-12-05       Impact factor: 19.871

Review 3.  Cyclic nucleotide phosphodiesterases: potential therapeutic targets for alcohol use disorder.

Authors:  Rui-Ting Wen; Fang-Fang Zhang; Han-Ting Zhang
Journal:  Psychopharmacology (Berl)       Date:  2018-04-16       Impact factor: 4.530

4.  Early-Ethanol Exposure Induced Region-Specific Changes in Metabolic Proteins in the Rat Brain: A Proteomics Study.

Authors:  Patricia C Swart; Vivienne A Russell; Nicolaas M Vlok; Jacqueline J Dimatelis
Journal:  J Mol Neurosci       Date:  2018-06-18       Impact factor: 3.444

5.  Methamidophos exposure during the early postnatal period of mice: immediate and late-emergent effects on the cholinergic and serotonergic systems and behavior.

Authors:  Carla S Lima; Ana C Dutra-Tavares; Fernanda Nunes; André L Nunes-Freitas; Anderson Ribeiro-Carvalho; Cláudio C Filgueiras; Alex C Manhães; Armando Meyer; Yael Abreu-Villaça
Journal:  Toxicol Sci       Date:  2013-04-17       Impact factor: 4.849

6.  Vinpocetine halts ketamine-induced schizophrenia-like deficits in rats: impact on BDNF and GSK-3β/β-catenin pathway.

Authors:  Hebatalla I Ahmed; Somaia A Abdel-Sattar; Heba S Zaky
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-08-06       Impact factor: 3.000

7.  Distinct neurobehavioral dysfunction based on the timing of developmental binge-like alcohol exposure.

Authors:  B Sadrian; M Lopez-Guzman; D A Wilson; M Saito
Journal:  Neuroscience       Date:  2014-09-18       Impact factor: 3.590

8.  Quantitative Determination of Vinpocetine in Dietary Supplements.

Authors:  John M T French; Matthew D King; Owen M McDougal
Journal:  Nat Prod Commun       Date:  2016-05       Impact factor: 0.986

Review 9.  Role of phosphodiesterase 1 in the pathophysiology of diseases and potential therapeutic opportunities.

Authors:  Arun Samidurai; Lei Xi; Anindita Das; Audra N Iness; Navin G Vigneshwar; Pin-Lan Li; Dinender K Singla; Sakthivel Muniyan; Surinder K Batra; Rakesh C Kukreja
Journal:  Pharmacol Ther       Date:  2021-04-22       Impact factor: 13.400

10.  Inhibition of phosphodiesterase 4 reduces ethanol intake and preference in C57BL/6J mice.

Authors:  Yuri A Blednov; Jillian M Benavidez; Mendy Black; R Adron Harris
Journal:  Front Neurosci       Date:  2014-05-27       Impact factor: 4.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.